News & Updates

TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients
TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients
20 Jan 2023
Ritlecitinib, brepocitinib superior to placebo for inducing remission in UC
Ritlecitinib, brepocitinib superior to placebo for inducing remission in UC
13 Jan 2023

Ritlecitinib and brepocitinib as induction therapies for ulcerative colitis (UC) appear to be more effective than placebo while having an acceptable short-term safety profile, according to the results of a phase IIb study.

Ritlecitinib, brepocitinib superior to placebo for inducing remission in UC
13 Jan 2023